糖尿病对结直肠癌分期和死亡风险的影响:一项基于人群的队列研究
该回顾性队列研究利用加拿大安大略省关联的人群健康数据库,纳入2007至2015年确诊的44,178例结直肠癌患者,其中11,822例(26.7%)患有糖尿病。调整结直肠癌筛查及其他协变量后,糖尿病与更晚分期(III或IV期)无显著关联(调整OR 0.97,95%CI 0.93,1.01),与全因死亡率升高相关(调整HR 1.08,95%CI 1.04,1.12),但癌症特异性生存相似(调整HR 1.0,95%CI 0.95,1.06)。
要点
- 糖尿病与结直肠癌诊断时更晚分期无显著关联(调整OR 0.97,95%CI 0.93,1.01)。
- 糖尿病与全因死亡率升高相关(调整HR 1.08,95%CI 1.04,1.12)。
- 糖尿病与癌症特异性生存相似(调整HR 1.0,95%CI 0.95,1.06)。
核心结论
- 患有糖尿病的结直肠癌患者诊断时更晚分期的可能性未增加,癌症特异性死亡率与无糖尿病者相似。
- 糖尿病与结直肠癌患者全因死亡率升高相关,提示需要对糖尿病结直肠癌生存者给予更多非癌症护理关注。
研究设计与样本
- 回顾性队列研究,使用加拿大安大略省关联的基于人群的健康数据库。
- 纳入2007至2015年确诊的44,178例结直肠癌个体,其中11,822例(26.7%)患有糖尿病。
主要发现
- 调整结直肠癌筛查及其他协变量后,糖尿病患者表现为更晚分期(III或IV期)的可能性未增加(调整OR 0.97,95%CI 0.93,1.01)。
- 中位随访2.63年(四分位距0.97-5.10年)期间,糖尿病与较高的全因死亡率相关(调整HR 1.08,95%CI 1.04,1.12)。
- 糖尿病与相似的癌症特异性生存相关(调整HR 1.0,95%CI 0.95,1.06)。
临床怎么用
- 作者认为,需要对患有糖尿病的结直肠癌生存者给予更多非癌症护理关注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes is associated with an increased incidence of colorectal cancer (CRC). There exists conflicting evidence regarding the impact of diabetes on CRC-specific mortality (herein also referred to as cancer-specific mortality). The objectives of this study were to determine whether diabetes is associated with a more advanced CRC stage at diagnosis and with higher all-cause and cancer-specific mortality. METHODS: This retrospective cohort study used linked, population-based health databases from Ontario, Canada. Among individuals diagnosed with CRC from 2007 to 2015, we compared the likelihood of presenting with later- (III or IV) vs early- (I or II) stage CRC between patients with and without diabetes adjusting for relevant covariates. We then determined the association between diabetes and all-cause and CRC-specific mortality, after adjusting for CRC stage at diagnosis and other covariates. RESULTS: Of the 44,178 individuals with CRC, 11,822 (26.7%) had diabetes. After adjustment for CRC screening and other covariates, individuals with diabetes were not more likely to present with later-stage CRC (adjusted OR 0.97, 95% CI 0.93, 1.01). Over a median follow-up of 2.63 (interquartile range [IQR] 0.97-5.10) years, diabetes was associated with higher all-cause mortality (adjusted HR 1.08, 95% CI 1.04, 1.12) but similar cancer-specific survival (adjusted HR 1.0, 95% CI 0.95, 1.06). CONCLUSIONS/INTERPRETATION: Individuals with diabetes who develop CRC are not more likely to present with a later stage of CRC and have similar cancer-specific mortality compared with those without diabetes. Diabetes was associated with higher all-cause mortality in CRC patients, indicating that greater attention to non-cancer care is needed for CRC survivors with diabetes.
引用
- Qiang JK, Sutradhar R, Giannakeas V, et al. Impact of diabetes on colorectal cancer stage and mortality risk: a population-based cohort study. Diabetologia. 2020. PMID: 31993714. doi:10.1007/s00125-020-05094-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。